We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Picankibart is a recombinant anti-interleukin 23p19 ...
European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results